Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...
Leerink Partners analyst Mike Kratky maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) on November 25 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback